Allied Health & Imaging · Independent exam preparation
Certified Histocompatibility Specialist (CHS): Interpretation and Laboratory Decisions Study Guide
Interpret HLA typing, antibody patterns, crossmatches and quality failures through specialist-level cases, calculations and reporting decisions for ACHI CHS preparation.
By CertMedbry · Updated 31 October 2026
Practise deciding whether a specimen is suitable, resolving discordant HLA results, interpreting transplant compatibility evidence and correcting laboratory failures. This selective guide develops 60 specialist-level concepts across all six CHS domains. The official ACHI CHS Exam Content Outline defines the full examination scope. Additional tasks requiring separate study include linkage disequilibrium and mutations, broader disease associations and vaccine eligibility, concentration and molarity calculations, detailed equipment selection, and applicable ASHI standards.
Try 20 free practice questionsWhat is the exam format?
Check the question types, timing and outline before planning your revision.
Which credential and examination does this guide cover?
This guide covers the Certified Histocompatibility Specialist examination administered by the American College of Histocompatibility and Immunogenetics. CHS is distinct from ACHI's Certified Histocompatibility Associate, Certified Histocompatibility Technologist and laboratory director examinations. ABHI was the certifying body's former name through October 2020; it is not a separate current CHS pathway.
ACHI Technologist Examinations · ACHI Examination Candidate Handbook, January 2026
How many questions are scored, and how long is testing?
The January 2026 handbook specifies 150 scored multiple-choice questions plus 20 unscored pretest questions, for 170 questions presented. Testing time is 3.5 hours. The handbook separately allows a four-hour appointment including instructions and related activities. Pretest questions are interspersed and do not affect pass/fail status.
How is CHS delivered, and what item styles are verified?
The handbook describes computer delivery at Pearson VUE testing centers and an OnVUE remote-proctoring option for CHS. Questions have four answer choices, appear one at a time and may be bookmarked or revisited during the time limit. The handbook does not identify an adaptive testing algorithm. These 20 practice questions are independent single-best-answer drills, without pass prediction.
Which blueprint and dates apply?
The issuer's currently linked CHS outline has revision 20250321 in its filename, but no printed effective date. The candidate handbook states January 2026 as its latest update and remains listed in the issuer's October 2026 resource hub. A filename revision date should not be represented as a formally announced implementation date.
ACHI Resource Hub · ACHI Certified Histocompatibility Specialist Exam Content Outline · ACHI Examination Candidate Handbook, January 2026
How are the official domains weighted?
The outline assigns 18 of 150 scored items to Pre-Analytical Systems, 23 to Analytical Systems, 32 to Post-Analytical Systems, 30 to Quality Systems, 32 to General Theory and Applications, and 15 to Supervisory Functions and Laboratory Management. Calculated percentages are 12%, 15.33%, 21.33%, 20%, 21.33% and 10%, respectively. This guide allocates 7, 9, 13, 12, 13 and 6 concepts in that order. Each 20-item practice set uses 2, 3, 4, 4, 5 and 2 items.
ACHI Certified Histocompatibility Specialist Exam Content Outline
What passing score should candidates target?
The handbook describes Angoff standard setting and statistical equating. It does not establish one numerical passing score applicable to every examination form. Use practice performance to identify reasoning gaps rather than treating a percentage on these drills as an official pass threshold.
How do eligibility and application information differ from tested content?
The January 2026 handbook lists CHS education requirements and at least five years of relevant full-time experience completed within the preceding ten years. CHA and CHT have different eligibility requirements. Application windows and other administrative details can change; consult the current issuer examination page and the applicable handbook before applying.
ACHI Technologist Examinations · ACHI Examination Candidate Handbook, January 2026
Which jurisdictions and technical references are used?
CLIA examples explicitly concern U.S. laboratories. OPTN guidance is used within its U.S. transplant laboratory context. These requirements should not be extended automatically to other jurisdictions. Technical references support laboratory mechanisms and interpretation; they do not replace the CHS outline. Supporting documents retain their own publication dates, including the 2017 ABO insert, 2022 abacavir label and 2015 IQCP workbook.
42 CFR 493.1242: Specimen Submission, Handling and Referral · Guidance Document for OPTN Histocompatibility Laboratory Bylaws and Policies · CDC/CMS: Developing an IQCP—A Step-by-Step Guide
These independently authored learning materials prepare for ACHI's Certified Histocompatibility Specialist credential. They are not official ACHI examination items or endorsed by ACHI.
Outline used: Verified for 2026-10-13 against ACHI's currently linked CHS Exam Content Outline and Examination Candidate Handbook, latest update January 2026. The outline filename identifies revision 20250321; its page does not state an effective date. The workbook label matches the official credential name; the assigned slug is preserved.
60 key concepts: understand, apply and avoid the traps
Work through the questions by exam domain. Explain the answer in your own words, try the example, then check the common pitfall.
Pre-Analytical Systems12% (18/150 items; calculated)
1.What establishes specimen identity before testing?
Specimen identity begins with agreement between the container label, the request and the laboratory's accession record. In a U.S. CLIA laboratory, written procedures must address labeling, acceptance, rejection and receipt documentation. A technically excellent assay cannot repair an unresolved identity error because its result may belong to another person. The discriminating question is whether the laboratory can establish the specimen's identity through its authorized process before linking any result to a patient.
Apply it
Two transplant candidates have similar names. One tube has a medical record number that conflicts with its request. Hold the specimen, document the discrepancy and use the laboratory's identity-resolution procedure before initiating patient-specific testing.
Common pitfall: Matching a surname or accepting an informal verbal reassurance does not resolve conflicting identifiers. Analytical reproducibility confirms the sample's result, not whose sample it is.
2.How does the requested assay determine specimen suitability?
Suitability depends on what the method measures and which specimen properties it requires. Antibody testing needs an appropriate serum or plasma preparation, cellular crossmatching requires usable donor cells, and molecular typing requires adequate nucleic acid. Collection instructions must therefore connect specimen type, container, volume and handling to the intended examination. A specimen acceptable for one assay may fail another. Evaluate suitability against the validated method rather than accepting a tube solely because it contains sufficient material.
Apply it
A referral includes extracted donor DNA and requests both molecular HLA typing and a cellular crossmatch. Accept the DNA only for procedures validated for that material and arrange an appropriate cellular specimen for the crossmatch.
Common pitfall: A shared donor identifier does not make specimen materials interchangeable. DNA cannot supply the intact cellular targets required for a physical cellular crossmatch assay.
42 CFR 493.1242: Specimen Submission, Handling and Referral · Guidance Document for OPTN Histocompatibility Laboratory Bylaws and Policies
3.Why must storage conditions follow the intended method?
Storage controls preserve the properties that an assay depends on, including antibody reactivity, cellular integrity or nucleic acid quality. Written procedures should specify transport conditions, processing, storage and rejection criteria appropriate to the examination. There is no single universally acceptable temperature or holding time for every histocompatibility specimen. When a condition falls outside the validated interval, the decision turns on documented suitability evidence and the affected assay, rather than appearance or convenience alone.
Apply it
A donor cell shipment arrives after an undocumented temperature excursion. Check transport records and the method's acceptance criteria, assess the affected cellular preparation and determine whether recollection or an alternative validated approach is required.
Common pitfall: An intact container does not prove preserved analyte performance. Applying a serum storage rule to a donor lymphocyte preparation can overlook method-specific deterioration risks.
4.When does a sensitizing event change specimen selection?
Transfusion, pregnancy and transplantation can alter an individual's HLA antibody profile. Compatibility assessment therefore needs both the specimen date and a relevant sensitization history. A negative result obtained before a new exposure cannot establish the antibody status after that exposure. The practical decision is whether available specimens adequately represent the current clinical situation and whether additional testing is needed under the laboratory's transplant program agreements. Historical antibody information remains relevant even when current reactivity is weak.
Apply it
A candidate's last negative antibody specimen predates several transfusions. Before using it for a donor compatibility assessment, identify the exposure dates and obtain testing that addresses the changed sensitization history under the program's established procedure.
Common pitfall: A previously negative screen is time-specific evidence. Treating it as permanent clearance ignores antibody changes that can follow a subsequent sensitizing event or exposure.
Guidance Document for OPTN Histocompatibility Laboratory Bylaws and Policies
5.Why retain informative historical antibody specimens?
Preserved specimens allow a laboratory to investigate earlier antibody reactivity and compare it with current findings. This is valuable when antibody levels decline, an unexpected crossmatch occurs or a historical donor-specific antibody needs confirmation. Retention must preserve identity, collection dates, storage conditions and traceable use. The decision is not simply whether an old tube exists, but whether a suitably preserved specimen answers a defined question that a current specimen cannot resolve by itself.
Apply it
Current serum shows little reactivity, but the record describes a strong prior antibody against a proposed donor antigen. Locate the traceable historical specimen and compare appropriate testing with current findings before finalizing the compatibility interpretation.
Common pitfall: Selecting only the most reactive historical result without checking specimen identity, assay context or preservation can create an unsupported risk assessment from incomparable laboratory evidence.
Guidance Document for OPTN Histocompatibility Laboratory Bylaws and Policies
6.What information makes a virtual crossmatch interpretable?
A virtual crossmatch compares supported recipient antibody specificities and history with donor HLA assignments. Before testing or interpretation, establish relevant specimen dates, intervening sensitizing events, therapeutic exposures, and the donor loci and resolution needed to evaluate each antibody. An untyped locus is an information gap, not evidence of antigen absence. A negative screen alone cannot complete this comparison. Any report should identify the particular unresolved target and the additional typing, antibody investigation or cellular testing needed to address it.
Apply it
A recipient has a well-supported HLA-DP antibody, but the donor record lacks DP typing. Request the missing assignment and state that the DP-related comparison remains unresolved; an unrestricted negative virtual crossmatch would imply evidence the laboratory does not have.
Common pitfall: A complete-looking summary of common loci can conceal a decisive omission. A generic limitation statement is less useful than naming the unresolved donor-antibody comparison.
Guidance Document for OPTN Histocompatibility Laboratory Bylaws and Policies
7.How should reagent condition affect assay readiness?
Reagent readiness includes identity, lot, expiration, storage history and required controls. A bottle's availability does not establish that it can produce valid results. Manufacturer instructions and the laboratory's quality procedures determine acceptable use, including evaluation of deterioration or unexpected reactions. For ABO reagents, correct technique and appropriate controls are integral to interpreting agglutination. Resolve a questionable reagent condition before patient testing rather than relying on the expected patient result to demonstrate reagent fitness.
Apply it
An anti-A reagent has an uncertain storage history after a refrigerator alarm. Quarantine it, review the excursion and applicable instructions, and establish acceptable performance or replace it before reporting patient ABO reactions.
Common pitfall: An unexpired date does not override an adverse storage event. Conversely, one expected patient reaction is an inadequate substitute for an appropriate reagent evaluation process.
DIAGAST Blood Grouping Reagents Anti-A, Anti-B and Anti-A,B: Package Insert · CDC/CMS: Developing an IQCP—A Step-by-Step Guide
Analytical Systems15.33% (23/150 items; calculated)
8.What does a single-antigen bead result measure?
A single-antigen bead assay assesses antibody binding to HLA antigens displayed on individual bead populations and reports fluorescence associated with that binding. The pattern can help assign antibody specificity, but signal depends on assay conditions, antigen presentation and interference as well as antibody. Interpret the pattern with controls and relevant donor typing. The decisive distinction is between detecting binding to an assay target and proving a particular magnitude of injury in a transplant recipient.
Apply it
A recipient reacts with several beads carrying a shared donor HLA target. Confirm the specificity pattern, review controls and interference, and compare with donor typing before describing the finding as donor-specific antibody.
Common pitfall: A bright bead does not independently establish antibody concentration, complement activity or graft rejection. Each of those conclusions requires evidence beyond a fluorescence signal alone.
Quantitative Evaluation of the Impact of Ethylenediaminetetraacetic Acid Pretreatment on Single-Antigen Bead Assay · Guidance Document for OPTN Histocompatibility Laboratory Bylaws and Policies
9.How do cytotoxic and flow crossmatches differ?
A complement-dependent cytotoxic crossmatch evaluates whether antibody binding, under the assay conditions, produces complement-mediated donor cell injury. A flow crossmatch detects immunoglobulin bound to donor cells using fluorescent detection and does not require that binding to produce cytotoxicity. Their endpoints therefore differ. A flow-positive, cytotoxic-negative combination can be analytically coherent. Interpretation must integrate cell populations, controls, recipient antibody specificity and donor typing rather than requiring both methods to produce identical classifications.
Apply it
A recipient has a reproducible positive flow crossmatch and a negative cytotoxic crossmatch. Review donor-specific antibody evidence and assay controls; do not dismiss the flow finding merely because detectable binding did not produce the cytotoxic endpoint.
Common pitfall: Treating all crossmatches as equivalent overlooks their different endpoints. A negative cytotoxic assay does not establish absence of every antibody capable of binding donor cells.
Guidance Document for OPTN Histocompatibility Laboratory Bylaws and Policies
10.How do T-cell and B-cell crossmatch patterns guide interpretation?
T and B lymphocyte populations provide different HLA target profiles: both express class I, whereas B cells additionally provide substantial class II expression. An isolated B-cell reaction can therefore be compatible with class II-directed antibody, but it does not establish that explanation by itself. Cell quality, background binding, treatment effects and antibody specificity must also be considered. Use the population pattern to formulate a testable explanation, then compare it with donor and recipient evidence.
Apply it
A donor crossmatch is negative with T cells and positive with B cells. The recipient has antibody against a donor class II antigen. Evaluate whether this specificity and the controls explain the population pattern before reporting compatibility.
Common pitfall: An isolated B-cell positive result is not synonymous with class II donor-specific antibody. Background and other assay effects can produce a similar cellular pattern.
Guidance Document for OPTN Histocompatibility Laboratory Bylaws and Policies · Effects of Various Concentrations of Pronase on Flow Cytometric Crossmatching Patients Treated With Rituximab and Donor HLA-Specific Antibodies
11.How does molecular typing resolution affect an HLA assignment?
Molecular typing resolves HLA variation only within the information generated and interpreted by the method. An allele-group assignment cannot automatically be expanded into a specific protein or full allele sequence. The IPD-IMGT/HLA database supplies officially named reference sequences, while the assay's coverage and ambiguity determine which assignments are justified. Select a reporting resolution that answers the clinical question without claiming distinctions the data cannot support. Additional testing may be needed when remaining alternatives affect compatibility.
Apply it
A donor result identifies HLA-A*02 but does not distinguish several second-field possibilities. A recipient antibody question depends on that distinction. Obtain appropriate additional typing rather than substituting the most common allele for the unresolved assignment.
Common pitfall: Population frequency may rank possible alleles but does not establish the individual's allele. A familiar two-field name cannot be inferred solely from a first-field result.
12.Why does sequence coverage determine typing ambiguity?
Two alleles can share the sequence examined by an assay while differing in an unexamined region. Such an assay cannot distinguish them without additional informative data. Ambiguity is therefore related to both the reference database and the regions actually assessed, rather than simply the number of characters in a reported name. Determine whether unresolved alternatives differ in protein sequence, expression or another clinically relevant property before deciding whether the existing result is adequate.
Apply it
A typing result has alternatives identical across the tested antigen-recognition exons but different elsewhere. Review whether those differences affect the requested interpretation, then select additional coverage only if it resolves a meaningful remaining question.
Common pitfall: More sequencing reads over the same uninformative region do not necessarily resolve ambiguity. The missing distinction may require coverage of a different region or phase information.
13.Which STR loci are informative for chimerism?
An informative short tandem repeat locus distinguishes donor and recipient genetic contributions using their pretransplant profiles. Shared alleles can limit attribution, so a marker is useful only when its pattern supports reliable separation or quantification under the method. Chimerism analysis compares posttransplant DNA with these reference profiles and appropriate mixture standards. Select informative loci before interpreting a donor percentage; counting every detected peak as uniquely donor or recipient can produce an incorrect estimate.
Apply it
At one STR locus, donor and recipient have identical alleles; at another, the recipient has a distinct allele. Use the discriminating marker within the validated calculation rather than treating the shared locus as equally informative.
Common pitfall: A strong, clean STR signal is not automatically informative. If donor and recipient share the same pattern, that locus may provide little mixture discrimination.
14.Why does cell-subset purity matter in chimerism testing?
A lineage-specific chimerism result describes the DNA contribution in the isolated cell fraction that was actually tested. If that fraction contains other cell populations, their donor and recipient proportions can influence the measured result. Purity therefore affects whether a value represents the intended lineage. Compare cell selection, purity assessment and specimen type when evaluating serial results. A change in measured donor fraction can reflect a changed cellular mixture rather than an equivalent biological change within the target lineage.
Apply it
Two CD3-enriched specimens show different donor fractions, but the second isolation has substantially poorer purity. Review the contamination and its likely contribution before interpreting the difference as a true change in T-cell chimerism.
Common pitfall: A lineage label on the report does not establish perfect purification. Ignoring measured purity can turn a cell-isolation difference into an apparent engraftment trend.
15.How do anti-A and anti-B establish forward ABO reactions?
Forward ABO grouping examines red-cell agglutination with reagents directed against A and B antigens. Under valid test conditions, anti-A reactivity supports detectable A antigen and anti-B reactivity supports detectable B antigen. Reagent-specific instructions govern technique, reading and controls. Interpret reactions only after excluding invalid conditions such as an unacceptable control. A forward reaction pattern identifies antigen expression in the tested red-cell population; it does not independently resolve every ABO discrepancy or transplant-related mixed population.
Apply it
Red cells agglutinate with anti-A but not anti-B, and required controls are acceptable. Interpret the forward pattern as supporting A antigen expression while completing the laboratory's required ABO confirmation and discrepancy checks.
Common pitfall: A reaction should not be classified solely by its apparent strength when controls are invalid. Anti-A,B is not a replacement for resolving conflicting individual reagent results.
DIAGAST Blood Grouping Reagents Anti-A, Anti-B and Anti-A,B: Package Insert
16.How does non-HLA STR genotyping establish a baseline identity profile?
Pretransplant STR typing assigns allele sizes at polymorphic repeat loci in donor and recipient DNA. These non-HLA markers provide genetic identity signatures used to select informative loci for later chimerism measurement. The baseline genotype and the posttransplant mixture percentage answer different questions: the first identifies distinguishable alleles; the second estimates their relative contributions using a validated method and mixture standards. Sharing an STR profile at one locus does not establish HLA compatibility.
Apply it
At a hypothetical STR locus, the recipient has validated fragment assignments of 154 and 162 base pairs and the donor has 158 and 170. The distinct baseline products support contributor discrimination. Use the validated mixture analysis to quantify subsequent specimens rather than treating the presence of donor products alone as complete donor engraftment.
Common pitfall: Do not turn one marker's peak pattern into a universal percentage calculation. Shared alleles, assay performance and the reference mixtures affect quantification.
UCSF Chimerism Testing and Engraftment Monitoring · ACHI Certified Histocompatibility Specialist Exam Content Outline
Post-Analytical Systems21.33% (32/150 items; calculated)
17.Why can EDTA increase a weak single-antigen bead signal?
Complement-associated interference can suppress detection of HLA antibody in untreated serum, so weak fluorescence does not always mean weak antibody binding. EDTA can reduce this interference by chelating ions required for complement activity. In affected samples, treated serum may produce a stronger signal. Interpret that change as evidence of an assay matrix effect, using a validated procedure and controls. The magnitude of the increase does not by itself quantify clinical pathogenicity or establish a universal treatment response.
Apply it
A highly sensitized recipient has unexpectedly weak untreated bead reactivity that increases markedly after validated EDTA treatment. Investigate complement interference and reassess the specificity pattern rather than concluding that the treatment created new antibody.
Common pitfall: Assuming every low signal represents low antibody can underestimate reactivity. Conversely, a treatment-associated increase does not establish a universal MFI-to-risk conversion for clinical decisions.
18.Why is MFI not an absolute antibody concentration?
Mean fluorescence intensity reflects assay signal rather than a universally calibrated amount of antibody. Antigen density, bead characteristics, saturation, interference and sample treatment can alter the relationship between binding and measured fluorescence. Comparisons require attention to method and conditions, especially across lots or laboratories. Use MFI as one component of pattern interpretation. A numerical difference becomes clinically informative only when its analytical context and the relevant donor specificity support the proposed conclusion.
Apply it
Two laboratories report different MFI values for the same HLA specificity. Review specimen treatment, platform conditions, reagent lots and interpretive criteria before describing the discrepancy as a biological increase in the patient's antibody.
Common pitfall: Applying one numerical threshold universally ignores method dependence. Neither doubling MFI nor halving MFI guarantees a corresponding change in antibody concentration or transplant injury risk.
19.How can dilution clarify an unexpected antibody result?
Dilution changes both antibody abundance and interfering serum components. When interference suppresses an untreated result, dilution may increase measured fluorescence despite reducing antibody concentration. That counterintuitive response supports investigation of interference rather than a simple concentration interpretation. Serial dilution also helps characterize reactivity beyond an undiluted signal, but its meaning depends on the validated assay and endpoint. Compare untreated, treated and diluted patterns without assuming that fluorescence must change proportionally with dilution.
Apply it
A bead yields a stronger signal at a 1:8 serum dilution than in neat serum. Check controls and a validated interference investigation before interpreting the neat result as the most reliable estimate of antibody reactivity.
Common pitfall: Multiplying diluted MFI by the dilution factor does not produce a validated antibody concentration. Signal behavior can be nonlinear because interference and saturation also change.
20.How can rituximab explain a positive B-cell flow crossmatch?
Rituximab in recipient serum can bind donor B-cell CD20. Fluorescent anti-human IgG then detects the bound therapeutic antibody, producing B-cell crossmatch reactivity without establishing HLA donor specificity. A negative virtual comparison and positive B-cell flow result therefore warrant review of treatment history alongside complete donor typing and HLA antibody testing. Pronase can reduce interference by degrading CD20, but it can also degrade HLA and mask weak donor-specific reactivity. A treatment-associated negative result requires validated comparisons that preserve sensitivity.
Apply it
After rituximab exposure, a recipient has a positive B-cell and negative T-cell flow crossmatch, with adequate donor typing and no detected HLA DSA. Compare available pretreatment serum and validated treated-versus-untreated cell testing with controls. Loss of B-cell reactivity supports drug interference; if weak HLA DSA is also present, a pronase-negative result cannot exclude it.
Common pitfall: Do not choose a pronase concentration simply because it makes the crossmatch negative. Evaluate weak-DSA detection and B-cell gating as well as interference reduction.
Effects of Various Concentrations of Pronase on Flow Cytometric Crossmatching Patients Treated With Rituximab and Donor HLA-Specific Antibodies · Guidance Document for OPTN Histocompatibility Laboratory Bylaws and Policies
21.How should historical antibody affect a current interpretation?
Antibody reactivity can fall below a current assay's detection or reporting threshold while remaining important to the patient's sensitization history. Historical specificity should therefore be reviewed alongside present findings, specimen timing and intervening exposures. Its significance depends on the reliability of the earlier evidence and whether the donor carries the target. The correct report distinguishes current detection from historical detection rather than erasing one or treating every historical signal as equally established and clinically equivalent.
Apply it
A donor carries an antigen against which the recipient previously had confirmed antibody, although the current specimen is negative. Include the documented history in the compatibility assessment and explain the difference between historical and current detection.
Common pitfall: Calling a patient 'never sensitized' because today's assay is negative discards relevant history. Conversely, an unconfirmed historical artifact should not become a permanent unquestioned specificity.
Guidance Document for OPTN Histocompatibility Laboratory Bylaws and Policies
22.How do primers, probes and polymerase predict a molecular assay failure?
Primers bind flanking sequences and provide starting points for polymerase-mediated DNA amplification. A sequence-specific probe binds a complementary target and supplies a detection distinction; a probe mismatch can reduce detection even when amplification succeeds. In a hypothetical allele-specific PCR assay, failure of one primer to bind can cause allele dropout and apparent homozygosity, while an inactive polymerase can prevent both target and amplification-control products. These patterns distinguish a target-specific failure from a broadly failed reaction.
Apply it
A sample appears homozygous, its independent amplification control passes, and an alternative primer pair detects a second allele. This supports primer-site dropout over global polymerase failure. If an independent amplicon is present but only one probe channel fails, investigate probe binding or detection instead. Confirm the assignment with validated alternative coverage before release.
Common pitfall: A passing control proves only the functions it actually challenges. It cannot exclude a mismatch confined to an allele-specific primer or probe site.
ACHI Certified Histocompatibility Specialist Exam Content Outline · IPD-IMGT/HLA Database
23.How can a discrepant HLA typing result be resolved?
A discrepant typing result requires comparison at the same level of resolution before concluding that the assignments conflict. A broad allele group and a more specific member of that group may be compatible descriptions. True inconsistencies require review of specimen identity, raw data, reference sequence versions, ambiguity and coverage. Resolve the discrepancy using informative evidence rather than selecting the newest or most detailed-looking report. If additional testing is needed, choose a method that addresses the actual unresolved distinction.
Apply it
An older report lists HLA-A*02 and a new report lists HLA-A*02:01. First determine whether the older result was intentionally lower resolution. Escalate only if the underlying assignments conflict beyond their reporting granularity.
Common pitfall: Different formatting or resolution does not automatically mean different biology. Conversely, an apparent match at the first field can conceal a meaningful second-field discrepancy.
24.When should an ABO reaction remain unresolved?
An ABO assignment should remain unresolved when reactions or controls do not support a valid, coherent interpretation. Unexpected agglutination requires review of identity, specimen condition, reagent performance, technique and relevant clinical history. A manufacturer insert establishes how its reagents are used; it does not justify forcing every atypical pattern into a routine group. Repeat or supplemental investigation should address the observed discrepancy, with communication that prevents an uncertain result from being treated as a confirmed assignment.
Apply it
A specimen shows unexpected reactivity in a required control alongside anti-A agglutination. Suspend final ABO assignment, investigate the control failure and repeat testing under valid conditions before linking the pattern to a group.
Common pitfall: Choosing the strongest patient reaction while ignoring an invalid control can produce a confident but unsupported ABO assignment. Expected history cannot substitute for valid current testing.
DIAGAST Blood Grouping Reagents Anti-A, Anti-B and Anti-A,B: Package Insert
25.How should serial chimerism results be compared?
A meaningful chimerism trend requires comparable specimen types, cell fractions, informative markers and analytical performance. Whole-blood and selected-lineage results may differ because they represent different mixtures. Changes near method limits also require caution. Review selection purity and the clinical sampling context before assigning biological meaning to a percentage change. Chimerism measures donor and recipient contributions in the tested material; it does not independently establish the cause of a change or diagnose relapse in every setting.
Apply it
A whole-blood result shows 95% donor contribution and a later selected T-cell result shows 75%. Compare like fractions and review purity before describing this as a 20-percentage-point decline in the same biological compartment.
Common pitfall: Subtracting percentages from different cell populations creates a misleading trend. A precise number can still answer a different biological question from the preceding measurement.
26.How should desensitization mechanisms shape interpretation of follow-up tests?
Desensitization seeks to reduce an existing immunologic barrier to transplantation. Plasma exchange removes circulating antibody, whereas rituximab targets CD20-positive B cells and does not directly eliminate all antibody-secreting plasma cells. Antibody can therefore persist or rebound despite B-cell depletion. Rituximab can also cause B-cell flow crossmatch interference. Follow-up interpretation must distinguish reduced circulating antibody, an altered cellular compartment and a treatment-related assay effect; none alone proves durable donor-specific tolerance.
Apply it
After plasma exchange and rituximab, a candidate has reduced HLA bead reactivity but a persistently positive B-cell flow crossmatch. Compare specimens at documented treatment intervals, assess residual HLA specificity and investigate CD20-mediated drug interference before calling the crossmatch evidence of failed antibody removal.
Common pitfall: A low B-cell count does not establish absence of circulating DSA, and a transiently negative antibody result does not establish eradication of immune memory.
ACHI Certified Histocompatibility Specialist Exam Content Outline · Effects of Various Concentrations of Pronase on Flow Cytometric Crossmatching Patients Treated With Rituximab and Donor HLA-Specific Antibodies · Guidance Document for OPTN Histocompatibility Laboratory Bylaws and Policies
27.What makes a histocompatibility report clinically interpretable?
A useful report connects the identified patient and specimen to the examination performed, its result and any limitation that affects interpretation. In U.S. CLIA practice, reporting requirements include necessary identifying information and relevant specimen or result qualifications. For histocompatibility, typing resolution, unresolved alternatives, specimen date and donor-specific context may be decisive. The report should allow the recipient to understand what was established and which clinical question remains unanswered, without requiring unsupported assumptions about the method.
Apply it
A molecular report contains an HLA assignment with unresolved alternatives relevant to donor matching. Include the supported assignment and specific ambiguity rather than presenting one preferred alternative as a definitive allele-level result.
Common pitfall: A result can be analytically correct yet clinically misleading if its limitation is omitted. Adding a generic disclaimer does not replace identifying the consequential uncertainty.
42 CFR 493.1291: Test Report · HLA Nomenclature: Naming Alleles
28.How should an erroneous released report be corrected?
In a U.S. CLIA laboratory, a detected reporting error requires prompt notification of the appropriate recipient, a corrected report and retention of both the original and corrected reports. The correction should make the changed information and its significance clear. Simply replacing the visible result can leave clinicians acting on an earlier version and destroys the audit trail. Assess whether the correction affects a time-sensitive transplant decision so that communication matches the potential clinical consequence.
Apply it
A released donor typing report contains a transcription error affecting antibody assignment. Notify the authorized clinical team promptly, issue a traceable corrected report and retain the original version with documentation of the correction and communication.
Common pitfall: Silently overwriting a report may hide the error from the people using it. Internal correction alone does not ensure that an earlier clinical interpretation is reconsidered.
29.When does a result require urgent direct communication?
U.S. CLIA reporting rules require immediate alerting when a result indicates an imminently life-threatening condition or designated panic or alert value. Histocompatibility laboratories also need defined communication arrangements for time-sensitive transplant findings. The decision depends on the result's clinical context and the laboratory's established criteria, rather than its numerical size alone. Direct communication should identify the patient, result, limitation and recipient, with documentation sufficient to show that the actionable information reached an appropriate person.
Apply it
A corrected compatibility interpretation arrives while an organ acceptance decision is active. Use the established urgent communication pathway, document the recipient and explain the changed interpretation rather than relying solely on routine electronic report availability.
Common pitfall: Posting a report does not prove that a time-critical finding was received. Conversely, not every positive antibody result automatically meets the same urgent alert criteria.
Quality Systems20% (30/150 items; calculated)
30.How do accuracy and precision answer different quality questions?
Accuracy concerns agreement with an accepted reference or expected result, whereas precision concerns agreement among repeated measurements. A system can repeatedly produce the same wrong answer, so good precision does not establish accuracy. Verification should examine the performance characteristic actually needed for the claim. For quantitative measurements, compare both bias and variation; for qualitative assignments, assess appropriate agreement and reproducibility. Choose materials that challenge relevant decision points rather than relying only on easily classified routine specimens.
Apply it
A new system repeatedly reports a reference mixture near 70% when its assigned donor fraction is 80%. The tight replicate grouping supports precision, while the consistent displacement identifies an accuracy problem requiring investigation.
Common pitfall: A small spread among replicates can look reassuring while masking systematic error. Repetition measures consistency; it cannot independently establish agreement with the correct target value.
31.When is verification different from establishing performance specifications?
Under 42 CFR 493.1253, an unmodified FDA-cleared or approved nonwaived system requires local verification of accuracy, precision and reportable range, plus confirmation that manufacturer reference intervals fit the patient population. For modified systems or systems without applicable manufacturer specifications or FDA clearance, establish accuracy, precision, analytical sensitivity, analytical specificity including interference, reportable range, reference intervals and other necessary characteristics, as applicable. Define the intended use before selecting studies, document applicability and acceptance criteria, and complete the required work before reporting patient results.
Apply it
Changing a cleared assay to an unlisted specimen type requires establishment of performance for that use. Assess agreement with appropriate reference results, reproducibility, reportable limits, low-level detection and matrix-specific interference or cross-reactivity. Evaluate reference intervals if relevant; document why any characteristic is inapplicable rather than silently omitting it.
Common pitfall: A commercial kit's original clearance does not establish performance in a modified specimen matrix. The CMS verification brochure alone does not define the full establishment requirements.
Federal Register :: Request Access · CMS: Verification of Performance Specifications
32.Why must an unacceptable control stop routine result release?
A control tests whether defined parts of the analytical process are performing acceptably. When a required control fails, the affected patient results lack the support that the control was intended to provide. Determine the scope of the failure, investigate its cause and restore acceptable performance before releasing affected results. The appropriate response depends on the control's function and the potential impact; a plausible patient pattern cannot substitute for evidence that the process met its acceptance criteria.
Apply it
An ABO reagent control is unexpectedly reactive during patient testing. Withhold the affected interpretation, investigate reagent and procedural factors, and repeat appropriate testing only after acceptable control performance has been demonstrated and documented.
Common pitfall: Repeating only the patient until an expected answer appears does not correct a control failure. Selective acceptance can conceal a continuing defect in the assay process.
DIAGAST Blood Grouping Reagents Anti-A, Anti-B and Anti-A,B: Package Insert · CDC/CMS: Developing an IQCP—A Step-by-Step Guide
33.How does calibration differ from calibration verification?
Calibration establishes or adjusts the relationship between instrument response and analyte amount. Calibration verification checks whether the existing calibration remains valid across the reportable range. Passing a routine control at one concentration does not demonstrate acceptable performance at low, middle and high concentrations. Under applicable U.S. CLIA guidance, select the appropriate verification materials and interval for the system. Distinguish an adjustment that changes the measurement relationship from a check that evaluates its continued validity.
Apply it
A quantitative system passes its middle-range control, but high-range verification material is unacceptable. Investigate the range-dependent problem rather than declaring the entire reportable range valid from the single acceptable routine control.
Common pitfall: Recalibrating and verifying are not interchangeable activities. Adjusting an instrument does not itself document acceptable performance across the range used to report patient results.
34.How does an IQCP risk assessment identify control needs?
An Individualized Quality Control Plan begins with a risk assessment of the testing process, including specimen, test system, reagents, environment and personnel. The assessment identifies where failures could occur and how existing or proposed controls reduce their effects. It should connect each meaningful risk to a practical control and supporting evidence. A plan based solely on manufacturer claims or an absence of past complaints does not demonstrate that local workflow risks have been evaluated.
Apply it
A laboratory's assay is technically stable, but weekend specimen handoffs produce identification errors. Include the handoff risk in the assessment and design a control that checks identity at that transition rather than adding only instrument controls.
Common pitfall: More analytical QC cannot necessarily detect a specimen mix-up. Controls must address the failure pathway identified, including risks occurring before or after the measurement step.
35.How should a quality control plan be monitored?
A control plan requires ongoing assessment because staffing, instruments, specimen patterns and workflow can change. Monitor relevant indicators, investigate failures and determine whether the controls still reduce the risks they were designed to address. A written plan is evidence of design, not evidence of continued effectiveness. Select measures connected to actual failure pathways, such as identification errors or invalid runs, and revise the plan when the observed performance shows that its assumptions no longer hold.
Apply it
After introducing a new courier route, specimen rejection rates rise despite unchanged analytical QC. Review transport conditions and the risk assessment, then assess whether revised packaging or handoff controls reduce the documented failures.
Common pitfall: An unchanged control chart does not establish that every part of the testing process remains safe. The monitored measure must be capable of detecting the emerging risk.
36.How must proficiency testing be handled in a U.S. CLIA laboratory?
Proficiency testing should be integrated into routine testing using the laboratory's ordinary personnel, methods and procedures to the extent required by the program. It evaluates the laboratory's own performance rather than a specially optimized exercise. Interlaboratory communication about PT results before the reporting deadline and referral for testing are prohibited in the circumstances described by CMS. If the routine workflow would send a patient specimen elsewhere, apply the PT-specific rules rather than automatically referring the challenge.
Apply it
A PT specimen produces an unexpected result, and a staff member proposes asking another laboratory to test it before submission. Stop the proposed referral and follow the laboratory's PT procedure while investigating through permitted internal processes.
Common pitfall: Calling a referral 'confirmation' does not remove the PT restriction. Extra repeats or special handling outside routine practice can also undermine a valid assessment of performance.
37.Why must records connect specimens, methods and report versions?
Traceable records allow a laboratory to reconstruct which specimen was tested, which result was produced and which report was communicated. Receipt documentation and retained original and corrected reports address different parts of that chain. Without those links, an investigation may identify an error but fail to determine which patients or decisions were affected. Record design should support reconstruction of the actual testing episode, including relevant dates and changes, rather than merely storing a final result.
Apply it
A reporting defect is discovered after several amended compatibility reports. Use accession records and retained report versions to identify affected specimens, compare communicated interpretations and establish who needs notification about each correction.
Common pitfall: Keeping only the latest report may simplify viewing but destroys evidence needed to understand prior clinical use. Traceability requires preserving meaningful relationships and historical versions.
42 CFR 493.1242: Specimen Submission, Handling and Referral · 42 CFR 493.1291: Test Report
38.How should a laboratory respond to a recurring process failure?
A recurring failure calls for investigation of the process that permits it, followed by corrective action and evidence that the action works. Immediate containment protects affected work, while cause analysis identifies factors such as handoffs, confusing instructions or unsuitable controls. Training may be appropriate when knowledge is deficient, but it cannot repair every system defect. Select an effectiveness measure related to the original failure and assess it over a meaningful period after the change.
Apply it
Several specimen labels are transposed at the same accession handoff. Contain affected work, map the handoff and redesign the identification check. Then track recurrence and near misses to determine whether the revised process prevents the error.
Common pitfall: Retraining everyone without identifying the failure mechanism may leave the same hazard in place. A completed action form is not evidence that the action reduced recurrence.
39.How can reagent-lot changes affect result comparability?
Reagent changes can alter analytical behavior even when the assay name remains unchanged. For single-antigen bead testing, antigen presentation and signal characteristics contribute to MFI, so numerical comparability requires evaluation rather than assumption. A lot assessment should use appropriate materials and predefined criteria linked to the laboratory's interpretive claims. Investigate a shift that affects specificity assignment or classification. Do not interpret every new-lot signal change as a new biological event in the patient.
Apply it
Several stable patient specimens show similar MFI shifts immediately after a bead-lot change. Compare retained material across lots under controlled conditions before attributing the shared shift to simultaneous changes in each patient's antibody profile.
Common pitfall: A new lot's acceptable controls do not automatically prove perfect numerical interchangeability with the previous lot. Evaluate the performance property needed for the intended comparison.
Quantitative Evaluation of the Impact of Ethylenediaminetetraacetic Acid Pretreatment on Single-Antigen Bead Assay · CDC/CMS: Developing an IQCP—A Step-by-Step Guide
40.Which materials best challenge a method's decision boundaries?
A performance study should include materials that test the claims and boundaries relevant to patient reporting. Strong positives and clear negatives can establish basic discrimination while missing weaknesses near a classification threshold or at a reportable-range limit. Choose specimens or characterized mixtures that address expected use, reproducibility and important limitations. Acceptance criteria should be set before results are reviewed so that the study tests a defined claim rather than redefining success around the observed data.
Apply it
A chimerism method will report low recipient contributions. Include appropriate mixtures near that intended reporting boundary, with replicate assessment, rather than validating the claim only with pure donor and equal donor-recipient mixtures.
Common pitfall: Excellent performance on easy specimens does not establish performance at a difficult boundary. Selecting acceptance limits after seeing results weakens the meaning of the evaluation.
CMS: Verification of Performance Specifications · UCSF Chimerism Testing and Engraftment Monitoring
41.How should laboratory staff control exposure from leaking specimen packages?
In the United States, the [OSHA Bloodborne Pathogens standard, 29 CFR 1910.1030](https://www.osha.gov/laws-regs/regulations/standardnumber/1910/1910.1030), requires engineering and work practice controls to minimize occupational exposure, with suitable PPE for remaining exposure. Apply universal precautions to human blood. Separate contaminated packages from clean supplies and place externally contaminated specimen containers in suitable secondary containment that prevents leakage. Select gloves and protective clothing for anticipated contact; add a mask with eye protection or an appropriate face shield when splashes could contaminate the eyes, nose or mouth.
Apply it
At an accession bench, isolate a leaking blood package from clean preparation materials. Wearing appropriate PPE, place it in closed, leak-resistant secondary containment, labeled or color-coded as required. Clean and decontaminate affected surfaces using the established procedure, appropriate disinfectant and required contact time. Remove contaminated PPE safely and wash hands after glove removal. Revise the bench layout to prevent recurrence.
Common pitfall: Gloves alone leave splash and environmental contamination pathways uncontrolled. Select controls for the actual task and update the exposure control plan when workflow changes affect exposure. IQCP addresses testing quality; OSHA establishes the cited U.S. occupational exposure requirements.
General Theory and Applications21.33% (32/150 items; calculated)
42.What do the fields in an HLA allele name distinguish?
An HLA allele name begins with the locus and an asterisk, followed by colon-separated fields. The first field identifies the allele group; the second distinguishes protein sequence differences; the third distinguishes synonymous coding differences; and the fourth distinguishes noncoding differences. Not every name contains all four fields. These levels answer different questions, so report resolution explicitly. A shared first field does not establish protein identity, while a later-field difference need not change the encoded protein.
Apply it
Two assignments share the first two fields but differ in the third. Recognize that the nomenclature distinguishes coding DNA without requiring a different protein sequence, and determine whether that distinction matters for the requested use.
Common pitfall: Counting matching characters is not a biological interpretation. The position of the differing field determines whether the named distinction concerns protein, synonymous coding or noncoding sequence.
43.How do HLA expression suffixes change interpretation?
An expression suffix adds information beyond the allele's numerical fields. For example, N designates a null allele, L low expression, S a secreted product, C cytoplasmic expression, A aberrant expression and Q questionable expression. These suffixes are not interchangeable and should be retained when relevant to an assignment. The key distinction is between detecting an allele's sequence and inferring the usual cell-surface antigen expression; an expression designation can alter that inference.
Apply it
A donor assignment includes an N suffix. Preserve the suffix and review its expression implication when comparing molecular typing with antibody targets rather than assuming the numerical allele name guarantees ordinary cell-surface expression.
Common pitfall: Removing a suffix to simplify a report can erase consequential information. Questionable expression is not equivalent to established null expression, and the two should remain distinct.
44.What does an HLA G group establish?
A G group combines alleles with identical nucleotide sequences across the exons encoding the peptide-binding domains: exons 2 and 3 for class I and exon 2 for class II. This is a defined regional sequence equivalence, not complete genomic identity. Alleles in the same group may differ outside those regions. Use the designation to describe the information it supports, and check additional allele characteristics when differences outside the grouped sequence could affect interpretation.
Apply it
A donor and recipient share a G-group assignment. State the supported identity across the specified peptide-binding exons, while checking whether the clinical question requires distinctions involving expression or sequence outside those grouped regions.
Common pitfall: A shared G group does not prove identical whole-gene sequence or identical expression. The group definition covers particular exons rather than every feature of each allele.
45.How are parental HLA haplotypes inherited?
An individual ordinarily inherits one HLA haplotype from each parent. Because HLA loci are linked, family analysis considers the inherited combinations across loci rather than treating every locus as an independent draw. Parental and sibling typings can help establish which alleles travel together. Recombination remains a possible explanation for an unusual family pattern, but identity errors and incomplete resolution also require consideration. Use the observed family data to support phase rather than assuming phase from unrelated population frequency.
Apply it
A family has parental haplotypes designated a/b and c/d. A child typed as a/c has inherited one haplotype from each parent. Use additional family results to assess a proposed sibling match and investigate unexpected locus combinations.
Common pitfall: Sharing an allele at one locus does not establish sharing the entire haplotype. Family phase requires linked information, and occasional recombination can disrupt an expected pattern.
46.How is full-sibling HLA matching probability calculated?
Under the standard two-parent haplotype model, a full sibling has a one-in-four chance of inheriting the same two haplotypes as the patient. There are two maternal choices and two paternal choices, producing four equally likely combinations. For multiple siblings, calculate the probability of no match and subtract it from one. This probability describes inheritance before typing; it does not guarantee a match in a particular family or replace actual HLA testing.
Apply it
For three full siblings under the standard model, the probability of at least one haplotype-identical match is 1 minus 0.75 cubed: 0.578125, or approximately 57.8%. Each sibling still requires individual typing.
Common pitfall: Adding 25% for each sibling incorrectly treats matching events as mutually exclusive. More than one sibling can match, so use the complement of no matches.
47.What structural features identify an HLA class I molecule?
The HLA-A2 structure illustrates a class I molecule containing an HLA alpha heavy chain associated with beta-2-microglobulin. The heavy chain supplies the peptide-binding platform, whereas beta-2-microglobulin is a separate supporting component. This architecture distinguishes class I from the alpha-and-beta-chain arrangement of class II. When interpreting a structural or reagent description, identify which chain is the polymorphic HLA product and which associated component contributes to the assembled complex.
Apply it
A diagram labels an HLA-A heavy chain and beta-2-microglobulin beside a peptide-binding platform. Identify the complex as class I and distinguish the associated light component from the HLA-A allele product itself.
Common pitfall: Calling beta-2-microglobulin the class II beta chain confuses two different molecular architectures. Similar words in component names do not establish equivalent structural roles or genetic loci.
RCSB PDB 1HLA: Human Class I Histocompatibility Antigen HLA-A2
48.What structural features identify an HLA class II molecule?
The HLA-DR1 peptide complex illustrates class II architecture: an alpha chain and a beta chain together form the peptide-binding platform. This differs from class I's heavy chain associated with beta-2-microglobulin. Both class II chains contribute to the assembled molecule, so relevant HLA assignments may require attention to the chain combination rather than a single abbreviated antigen label. Structural recognition helps connect molecular typing information with the actual antigenic target represented in an assay.
Apply it
A teaching image shows a peptide resting between HLA-DR alpha and beta chains. Classify the complex as class II and identify both chains as parts of the binding platform rather than searching for beta-2-microglobulin.
Common pitfall: Assuming every HLA molecule uses the class I arrangement obscures class II chain pairing. A beta chain in class II is not beta-2-microglobulin.
RCSB PDB 1DLH: HLA-DR1 Complexed with an Influenza Virus Peptide
49.How do primary and secondary immune responses affect compatibility assessment?
A primary adaptive response begins with activation and expansion of antigen-specific naive lymphocytes and generates effector and memory populations. Re-exposure can recruit memory cells, producing a faster response that commonly includes class-switched, affinity-matured antibody. Circulating antibody and immune memory are different measurements: antibody may become undetectable while memory persists. Consequently, a current negative HLA antibody result does not erase a documented previous response to an antigen carried by a proposed donor.
Apply it
A previously sensitized candidate currently lacks detectable antibody against an antigen present in a new donor. Compared with an otherwise similar candidate with no documented prior response, the historical specificity supports concern for an anamnestic response after re-exposure. Preserve that history and obtain appropriately timed follow-up evidence rather than declaring identical immunologic risk.
Common pitfall: A sensitizing exposure does not prove that antibody formed, and a negative serum test does not directly measure or exclude antigen-specific memory cells.
ACHI Certified Histocompatibility Specialist Exam Content Outline · Guidance Document for OPTN Histocompatibility Laboratory Bylaws and Policies
50.Which Banff 2022 criteria establish active kidney antibody-mediated rejection?
The displayed Banff 2022 criteria require three groups for active antibody-mediated rejection (AMR). The scores g and ptc denote glomerulitis and peritubular capillaritis. First, at least one active-injury alternative: microvascular inflammation (g > 0 and/or ptc > 0), intimal or transmural arteritis (v > 0), or acute thrombotic microangiopathy without another cause. The microvascular alternative requires absence of recurrent or de novo glomerulonephritis; concurrent infection, borderline changes or acute T-cell-mediated rejection (TCMR) requires g ≥ 1. Second, antibody-endothelial interaction: qualifying C4d, g + ptc ≥ 2 with those same microvascular qualifications, or thoroughly validated biopsy AMR/MVI transcript diagnostics above a defined threshold. Qualifying C4d requires linear staining in peritubular capillaries or medullary vasa recta: C4d2/3 by immunofluorescence on frozen sections or C4d > 0 by immunohistochemistry on paraffin sections. Third, circulating donor-specific antibodies (DSA); qualifying C4d may substitute, but thorough DSA testing remains recommended.
Apply it
Without glomerulonephritis, concurrent infection/TCMR or qualifying chronic lesions, g1/ptc1 plus current DSA meets all three groups despite negative C4d. With infection, g0/ptc2, negative C4d, no qualifying transcripts and no other active-injury lesion fails both microvascular criteria despite DSA.
Common pitfall: DSA alone does not establish rejection. Unexplained acute tubular injury alone is not a qualifying active-injury alternative. Chronic active AMR requires qualifying chronic injury—transplant glomerulopathy after excluding chronic thrombotic microangiopathy and recurrent/de novo glomerulonephritis, or severe peritubular capillary basement membrane multilayering—plus the same interaction and serologic criteria.
Banff Foundation: Reference Guide to the Banff Classification
51.How does HLA-B*57:01 screening relate to abacavir hypersensitivity and restart decisions?
The abacavir and lamivudine label requires HLA-B*5701 screening before initiation or reinitiation unless a documented result exists; a positive result contraindicates the product. Stop immediately when hypersensitivity is suspected. If hypersensitivity cannot be ruled out, do not restart any abacavir-containing product, regardless of genotype. If hypersensitivity is clinically ruled out, the label permits clinician-directed restart with medical care readily accessible. A negative HLA-B*57:01 result alone neither excludes clinical hypersensitivity nor establishes eligibility to restart.
Apply it
A patient stopped abacavir for a suspected reaction and subsequently tests negative for HLA-B*57:01. The genotype does not authorize restart. If clinical evaluation cannot rule out hypersensitivity, no restart is permitted; if it rules hypersensitivity out, the label's medically supervised restart provision may apply.
Common pitfall: Symptom resolution or a negative genotype does not independently rule out the prior reaction. Distinguish clinical exclusion from persistent diagnostic uncertainty.
52.How is a serum dilution calculated?
A dilution expresses the original specimen volume as a fraction of the final mixture. One part serum plus three parts diluent is a 1:4 dilution, because serum constitutes one of four total parts. Serial dilution factors multiply: a 1:4 preparation followed by a further 1:2 dilution gives an overall 1:8 dilution. Record preparation volumes and cumulative factors accurately. Correct dilution arithmetic supports reproducible testing but does not make assay fluorescence linearly proportional to antibody concentration.
Apply it
Mix 25 microliters of serum with 75 microliters of diluent to prepare 1:4. Then mix equal volumes of that preparation and diluent to obtain 1:8 overall, documenting both preparation steps and the final cumulative factor.
Common pitfall: Confusing serum-to-diluent ratio with serum-to-total-volume ratio gives the wrong factor. Even correct arithmetic does not justify multiplying MFI into an absolute antibody concentration estimate.
53.How do donor and recipient fractions relate in a defined mixture?
In a valid two-contributor chimerism model, donor and recipient fractions describe complementary contributions to the tested material and sum to 100%. This relationship assumes the method appropriately distinguishes those contributors and the specimen fits the model. A reported fraction remains specific to the analyzed cell population and method. Percent donor DNA should not automatically be interpreted as the percentage of every tissue or as proof of a particular disease state throughout the patient.
Apply it
A validated analysis of a defined two-contributor cell fraction reports 92% donor contribution. The complementary recipient contribution is 8%, provided the method's assumptions hold; retain the cell-fraction designation when reporting and comparing the result.
Common pitfall: The complement calculation does not cure uninformative markers, poor purity or an invalid contributor model. Correct subtraction can still be attached to an inappropriate biological interpretation.
54.How do tolerance and immunosuppression differ mechanistically?
Immunologic tolerance is antigen-specific unresponsiveness supported by mechanisms such as deletion of reactive clones, anergy or regulatory suppression. Pharmacologic immunosuppression reduces immune activation, proliferation or effector function while treatment acts and can affect responses to many antigens. Neither reduced antibody after desensitization nor stable graft function during immunosuppression independently demonstrates donor-specific tolerance. The compatibility implication is that the donor's HLA targets and the recipient's established sensitization remain relevant even when treatment suppresses current measurable responses.
Apply it
A recipient has stable graft function and no detectable DSA while receiving immunosuppression. These observations support the current clinical state but do not identify whether donor-reactive clones were deleted, rendered unresponsive or merely suppressed by treatment. Do not infer that a negative assay establishes tolerance or makes treatment withdrawal appropriate.
Common pitfall: A treatment-associated reduction in immune activity is not direct evidence of durable antigen-specific unresponsiveness. Absence of circulating antibody does not assess every cellular rejection mechanism.
ACHI Certified Histocompatibility Specialist Exam Content Outline · Guidance Document for OPTN Histocompatibility Laboratory Bylaws and Policies
Supervisory Functions and Laboratory Management10% (15/150 items; calculated)
55.How should staffing reflect demonstrated testing competence?
A staffing plan should connect expected workload and required turnaround with personnel who are authorized and demonstrably competent for the assigned procedures. Headcount alone does not establish coverage when only some staff can perform a specialized assay or resolve a discrepancy. Identify vulnerable periods, backup skills and escalation arrangements. Competency records provide evidence for assignment decisions, while workload analysis shows whether the available skills can meet routine demand and foreseeable urgent requests without bypassing quality controls.
Apply it
A weekend roster includes three staff members, but only one is assessed for urgent flow crossmatching. Build qualified backup coverage and an escalation plan rather than treating three scheduled people as three interchangeable crossmatch operators.
Common pitfall: Experience in another assay does not automatically establish competence in the assigned procedure. A numerically adequate roster may still contain a critical skill or authorization gap.
CMS: Assessing Personnel Competency · ACHI Certified Histocompatibility Specialist Exam Content Outline
56.Which activities establish a comprehensive competency assessment?
CMS describes six competency assessment procedures: direct observation of testing; monitoring recording and reporting; review of worksheets, QC, PT and maintenance records; direct observation of maintenance and function checks; assessment with previously analyzed, blind or PT material; and assessment of problem-solving skills. These procedures examine different aspects of actual performance. Training attendance or one successful challenge cannot replace the applicable assessment activities. Link the evidence to the individual's assigned testing responsibilities and document the resulting evaluation.
Apply it
A technologist passes a blind specimen but has no observed maintenance or reporting assessment. Complete the remaining applicable activities and evaluate problem solving before treating the single successful specimen as comprehensive competency documentation.
Common pitfall: Training records show instruction occurred; they do not establish independent performance. PT success supplies only part of the evidence needed for a comprehensive competency assessment.
57.How should a competency gap be remediated?
Remediation should target the demonstrated gap, reduce the immediate risk and reassess the relevant performance after corrective instruction or practice. A documentation error, an interpretation error and an instrument-maintenance error require different responses. Determine whether the person understands the procedure, can perform it and can recognize failure conditions. Restore independent assignment based on evidence of corrected performance under the laboratory's process, rather than relying only on elapsed training time or a signed attendance sheet.
Apply it
An operator performs an assay correctly but releases results despite a failed control. Restrict the affected independent task, teach the release decision and reassess with scenarios requiring recognition and resolution of unacceptable control performance.
Common pitfall: Repeating the entire training program may miss a specific decision deficit. Conversely, a verbal explanation alone may not demonstrate that corrected behavior transfers to actual work.
58.How should cost per reportable result be calculated?
Cost per reportable result divides the defined total cost by the number of usable reported results, rather than by specimens loaded or reagent reactions purchased. The numerator may include reagents, controls, repeats, labor and allocated instrument costs, depending on the decision being evaluated. State those boundaries explicitly. A lower kit price may still produce a higher cost per result if failure rates or staffing needs increase. Combine financial analysis with the required quality and service performance.
Apply it
A monthly service costs $12,000 within the stated accounting scope and produces 240 reportable results after controls and failed runs. Its cost is $50 per reportable result; compare alternatives using the same cost boundaries and denominator.
Common pitfall: Dividing by every attempted reaction understates cost when some reactions are controls or failures. Comparing differently defined cost totals can also create a misleading purchasing advantage.
ACHI Certified Histocompatibility Specialist Exam Content Outline
59.How can inventory planning preserve testing continuity?
Inventory planning balances expected consumption, supplier lead time, expiration, storage capacity and the consequences of a stockout. A reorder point based on average use alone may fail when demand rises or delivery is delayed. Conversely, excessive purchasing can increase expiration losses and storage risk. Track usable stock by lot and condition, with contingency arrangements for essential assays. The goal is reliable availability of acceptable materials, rather than maximizing the quantity physically present in the laboratory.
Apply it
An essential reagent is used at ten kits weekly and has a three-week replenishment time. Establish a reorder plan covering expected lead-time use plus a justified reserve, while accounting for existing stock's expiration and storage requirements.
Common pitfall: Counting expired, quarantined or unsuitable material as available stock exaggerates readiness. A reserve is useful only if it remains usable and accessible when the assay is needed.
ACHI Certified Histocompatibility Specialist Exam Content Outline · CDC/CMS: Developing an IQCP—A Step-by-Step Guide
60.How should workflow capacity be evaluated for urgent testing?
Capacity depends on the slowest limiting resource across specimen processing, instrument access, qualified personnel and result review. Adding an instrument will not remove a bottleneck caused by unavailable competent reviewers. Map the sequence and distinguish hands-on time from elapsed time, including controls, repeats and communication. Evaluate whether a proposed schedule or resource change improves the required turnaround under realistic demand. Maintain the quality steps that make the final result valid while addressing the actual constraint.
Apply it
Urgent crossmatches wait two hours for authorized interpretation even when testing finishes promptly. Examine qualified review coverage and escalation arrangements before buying another analyzer, then measure whether the revised coverage improves the complete specimen-to-report interval.
Common pitfall: Instrument throughput is not the same as service turnaround. Optimizing a fast analytical step may provide little benefit when another step remains the dominant source of delay.
ACHI Certified Histocompatibility Specialist Exam Content Outline · CMS: Assessing Personnel Competency
What to focus on during revision
The following are CertMedbry study suggestions. Use the official outline to check the full scope of your examination.
- Connect specimen dates and sensitization events to the validity of a compatibility assessment.
- Separate antibody detection, donor specificity, cellular binding and tissue injury as distinct evidentiary steps.
- Interpret HLA resolution, expression suffixes and G groups without claiming unsupported sequence identity.
- Resolve interference and discordance using hypotheses that predict observable assay patterns, including rituximab interference and primer or probe failure.
- Compare chimerism results only after checking baseline non-HLA genotypes, informative markers, cell fractions and selection purity.
- Distinguish immune memory, tolerance, desensitization and immunosuppression when interpreting compatibility evidence.
- Practise traceable reporting, corrected reports and context-specific urgent communication.
- Distinguish accuracy, precision, verification, performance establishment, calibration and ongoing quality assessment.
- Use competency evidence, workload constraints and cost per reportable result for specialist management decisions.
A practical preparation plan
1. Map the complete CHS outline
Use the official six-domain outline as the full scope. Mark each task as secure, uncertain or unfamiliar. Study the additional tasks identified in the introduction alongside these selected concepts, giving substantial time to post-analytical systems, quality systems and theory.
2. Build specimen-to-report reasoning
For each case, identify the specimen, clinical question, assay endpoint, acceptance evidence and reporting limitation. Explain how a failure at each stage could change the final interpretation.
3. Practise paired distinctions
Contrast current with historical antibody, primary with secondary responses, tolerance with treatment-related suppression, flow with cytotoxic crossmatching, and verification with performance establishment. State the observation that separates each pair.
4. Work calculations with assumptions
Calculate cumulative dilutions, sibling-match probabilities, complementary chimerism fractions and cost per reportable result. Write the denominator and biological or accounting assumptions before calculating.
5. Use the drills diagnostically
Complete the 20 questions independently, then explain why each alternative fails. Revisit the linked concept and supporting source for reasoning errors rather than memorizing the correct option's position.
6. Rehearse specialist communication
Write brief interpretations for incomplete donor typing, rituximab interference, suspected allele dropout, discrepant chimerism and corrected reports. For biopsy cases, identify each required active AMR criterion and explain why a near miss does not qualify.
Use your sample score as a starting point
The free set contains 20 original practice questions. It is a small learning sample, not an official examination or a validated pass prediction. Review each explanation and its source before moving to another topic.
Start the free sampleOfficial sources and updates
- ACHI Resource Hub
- ACHI Technologist Examinations
- ACHI Examination Candidate Handbook, January 2026
- ACHI Certified Histocompatibility Specialist Exam Content Outline
- HLA Nomenclature: Naming Alleles
- HLA Nomenclature: G Groups
- IPD-IMGT/HLA Database
- Guidance Document for OPTN Histocompatibility Laboratory Bylaws and Policies
- Quantitative Evaluation of the Impact of Ethylenediaminetetraacetic Acid Pretreatment on Single-Antigen Bead Assay
- UCSF Chimerism Testing and Engraftment Monitoring
- DIAGAST Blood Grouping Reagents Anti-A, Anti-B and Anti-A,B: Package Insert
- NMDP: What Is HLA?
- RCSB PDB 1HLA: Human Class I Histocompatibility Antigen HLA-A2
- RCSB PDB 1DLH: HLA-DR1 Complexed with an Influenza Virus Peptide
- Banff Foundation: Reference Guide to the Banff Classification
- Abacavir and Lamivudine Tablets: Prescribing Information
- 42 CFR 493.1242: Specimen Submission, Handling and Referral
- 42 CFR 493.1291: Test Report
- CMS: Verification of Performance Specifications
- CMS: Proficiency Testing and PT Referral
- CMS: Assessing Personnel Competency
- CDC/CMS: Developing an IQCP—A Step-by-Step Guide
- CMS: Calibration and Calibration Verification
- Federal Register :: Request Access
- Effects of Various Concentrations of Pronase on Flow Cytometric Crossmatching Patients Treated With Rituximab and Donor HLA-Specific Antibodies
- Kidney Transplant for Highly Sensitized Patients - UChicago Medicine
- Frontiers Publishing Partnerships | European Guideline for the Management of Kidney Transplant Patients With HLA Antibodies: By the European Society for Organ Transplantation Working Group
- CD4+ T cell anergy prevents autoimmunity and generates regulatory T cell precursors - PMC
Confirm current eligibility, fees, scheduling and policies directly with the examination provider. CertMedbry is independent and is not endorsed by these organisations. How we handle content and corrections.